Morepen Laboratories Limited — Others, 12-05-2025: Appointment

Morepen Laboratories has announced a board meeting approving the financial results for the quarter and year ended March 31, 2025, along with a proposed final dividend of Rs. 0.20 per share, subject to shareholder approval. The company amended the transfer date of its medical devices business to subsidiary Morepen Medipath, which plans to set up a wholly owned step-down subsidiary in Dubai to boost international expansion. New Cost and Internal Auditors were appointed for FY 2025-26, with unqualified audit opinions on the results.